Is Tinzaparin-Sodium compatible with breastfeeding? Do we have alternatives for Tinzaparin-Sodium?

Tinzaparin-Sodium

November 25, 2014 (Very Low Risk)

This is a Heparin with low molecular weight.

At latest update, relevant published data on its excretion into breast milk were not found.

The high molecular weight of the so-called Standard or non-fragmented Heparin and others called low weight Heparins makes that excretion into breast milk very unlikely.

There is published evidence of a lack of anti-coagulant activity in the serum of breastfed infants whose mothers were treated with Enoxaparin.

There is scientific proof on the lack of excretion of Dalteparin into breast milk.

In addition, Heparin derived drugs are inactivated in the gut and they are not absorbed at all, hence, oral bioavailability is nil.

The risk of Heparin-induced Thrombocytopenia and Osteoporosis is lower with low weight Heparin among treated adults.

Alternatives

Very Low Risk

Compatible. Not risky for breastfeeding or infant.

Low Risk

Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.

High Risk

Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.

Very High Risk

Not recommended. Cessation of breastfeeding or alternative.

Synonyms

  • チンザパリンナトリウム
  • تينزابارين صوديوم
  • τινζαπαρίνη νατριούχος
  • Тинзапарин Натрий
  • 亭扎肝素钠

Drug trade names

References

  1. Noviani M, Wasserman S, Clowse ME. Breastfeeding in mothers with systemic lupus erythematosus. Lupus. 2016Abstract
  2. Ozdemir D, Tam AA, Dirikoc A, Ersoy R, Cakir B. Postpartum osteoporosis and vertebral fractures in two patients treated with enoxaparin during pregnancy. Osteoporos Int. 2014Abstract
  3. Fuller KP, Turner G, Polavarapu S, Prabulos AM. Guidelines for use of anticoagulation in pregnancy. Clin Lab Med. 2013Abstract
  4. Yurdakök M. Fetal and neonatal effects of anticoagulants used in pregnancy: a review. Turk J Pediatr. 2012Abstract Full text (link to original source) Full text (in our servers)
  5. Middeldorp S. How I treat pregnancy-related venous thromboembolism. Blood. 2011Abstract Full text (link to original source) Full text (in our servers)
  6. Rath W. [Thromboprophylaxis during pregnancy and the puerperium: highlights from current guidelines]. Z Geburtshilfe Neonatol. 2010Abstract
  7. Lindhoff-Last E, Bauersachs R. Heparin-induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation. Semin Thromb Hemost. 2002Abstract
  8. Wautrecht JC. [Which anticoagulants?]. Rev Med Brux. 2002Abstract
  9. Richter C, Sitzmann J, Lang P, Weitzel H, Huch A, Huch R. Excretion of low molecular weight heparin in human milk. Br J Clin Pharmacol. 2001Abstract Full text (link to original source) Full text (in our servers)
  10. Lindhoff-Last E, Willeke A, Thalhammer C, Nowak G, Bauersachs R. Hirudin treatment in a breastfeeding woman. Lancet. 2000Abstract
  11. Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med. 2000Abstract Full text (link to original source) Full text (in our servers)
  12. Bates SM, Ginsberg JS. Anticoagulants in pregnancy: fetal effects. Baillieres Clin Obstet Gynaecol. 1997Abstract
  13. Guillonneau M, de Crepy A, Aufrant C, Hurtaud-Roux MF, Jacqz-Aigrain E. [Breast-feeding is possible in case of maternal treatment with enoxaparin]. Arch Pediatr. 1996Abstract
  14. Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 1992Abstract
  15. Wunderer G, Müller G. [Osteoporosis and pre- and postpartal heparin therapy]. Geburtshilfe Frauenheilkd. 1990Abstract
  16. Ginsberg JS, Hirsh J. Optimum use of anticoagulants in pregnancy. Drugs. 1988Abstract
  17. Estes JW. Clinical pharmacokinetics of heparin. Clin Pharmacokinet. 1980Abstract